Paper Details

  1. Home
  2. Paper Details

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.

Author: AndreolaGiovanna, BertoliniFrancesco, BillioAtto, CalabreseLiliana, FabbriAlberto, FrigeriFerdinando, LaszloDaniele, MancusoPatrizia, MartinelliGiovanni, PintoAntonello, PruneriGiancarlo, RabascioCristina, RadiceDavide, RigacciLuigi

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the efficacy of 2-chloro-2'-deoxyadenosine (2-CdA) given subcutaneously in combination with rituximab in the treatment of newly diagnosed/pretreated patients with Waldenström macroglobulinemia (WM).
Paper Details　
Original Abstract of the Article :
To assess the efficacy of 2-chloro-2'-deoxyadenosine (2-CdA) given subcutaneously (SC) in combination with rituximab in the treatment of newly diagnosed/pretreated patients with Waldenström macroglobulinemia (WM) and to correlate the response to treatment with biologic findings (immunophenotypic and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2009.23.6315

データ提供：米国国立医学図書館（NLM）

A Combined Approach to Treating Waldenstrom Macroglobulinemia

Navigating the intricate landscape of [hematological malignancies] can be a daunting task. This study delves into the treatment of [Waldenstrom macroglobulinemia], exploring the efficacy of a combined approach using [rituximab] and [2-chloro-2'-deoxyadenosine (2-CdA)] administered subcutaneously.

A Phase II Study: Assessing the Efficacy of a Novel Treatment

The researchers conducted a Phase II multicenter study to evaluate the effectiveness of this combined therapy in newly diagnosed and previously treated patients with Waldenstrom macroglobulinemia. The study aims to determine the correlation between treatment response and biological findings, including immunophenotypic and pharmacogenomic analysis.

Advancing Treatment Strategies for Waldenstrom Macroglobulinemia

This research contributes to the development of more effective treatment strategies for Waldenstrom macroglobulinemia. The study's findings provide valuable insights into the potential of a combined therapy approach and offer a promising avenue for future research and clinical practice.

Dr.Camel's Conclusion

In the vast desert of cancer research, we seek innovative treatment strategies that can effectively combat this formidable adversary. This study provides a glimpse of a promising new approach to treating Waldenstrom macroglobulinemia, offering hope for a brighter future for patients facing this challenging disease.
Date :
  1. Date Completed 2010-05-13
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

20368573

DOI: Digital Object Identifier

10.1200/JCO.2009.23.6315

Related Literature

Article Analysis
・Effects of cladribine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.